Text and Data Mining valid from 2019-05-22
Received: 11 January 2019
Accepted: 23 April 2019
First Online: 22 May 2019
Change Date: 4 July 2019
Change Type: Correction
Change Details: Following publication of the original article , the author reported that an author name, Roberta Zappasodi, was missed in the authorship list.
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: AB is an employee and stockholder of Gilead. AC is an employee and stockholder of Nanostring. AJM has a research contract with Merck. AS is an employee of Merck. DD is an employee and options holder of Calidi Biotherapeutics. DDC holds a research grant from Nektar Therapeutics. DGD served as a consultant to Bristol-Myers Squibb, Merck, Pfizer, Adheare, Gossamer and Halozyme and received research support from Bristol-Myers Squibb. HM receives research funding from Adaptive Biotechnologies and has served on the advisory committee at AstraZeneca. HR is an employee of Bayer HealthCare Pharmaceuticals Inc. and shareholder of Bayer AG. JBW is the founder of MiraDx which holds IP regarding microRNA germline variants. JG is a cofounder and stakeholder of HalioDx, holds contracts with Perkin Elmer, IO Biotech, MedImmune and Janssen, is a consultant for BMS, Roche, GSK, Compugen and Mologen, and serves on the scientific advisory boards at Bristol-Myers Squibb, MedImmune, AstraZeneca, Novartis, Definiens, Merck-Serono, IO Biotech, ImmuneID, Nanostring, Illumina, Northwest Biotherapeutics, Actelion, Amgen, and Kite Pharma. HLK is an employee of Replimune, Inc. JJL served on the data and safety monitoring board at TTC Oncology and the scientific advisory boards at 7 Hills, Actym, Alphamab Oncology, Array, BeneVir and Mavu. JJL has also been a consultant for Aduro, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Castle, CheckMate, Compugen, EMD Serono, IDEAYA, Immunoscore, Janssean, Jounce, Merck, NewLink, Novartis, RefleXion, Spring Bank, Syndax, Tempest, Vividion and WntRx. JJL has received research support for clinical trials from Abbvie, Boston Biomedical, Bristol-Myers Squibb, Celldex, Compugen, Corvus, EMD Serono, Delcath, Five Prime, FLX Bio, Genentech, Immunoscore, Incyte, Leap, MedImmune, Macrogenics, Novartis, Pharmacyclics, Merck, Tesaro and Xencor, and holds scientific research agreements with Array, CheckMate, Evelo and Palleon. JJL has received travel awards from Array, AstraZeneca, Bayer, BeneVir, Bristol-Myers Squibb, Castle, CheckMate, EMD Serono, IDEAYA, Immunoscore, Janssen, Jounce, Merck, NewLink, Novartis and RefleXion. JS is an employee and shareholder of Abbvie. KKW has received consulting fees from Janssen, Pfizer, Eli Lilly and Astrazeneca, holds research contracts with Janssen, Novartis and BMS, and is a GI Therapeutics shareholder. KP (Palucka) has received consulting fees from and is a shareholder of Cue Biopharma, and holds a research contract with Merck. KP (Politi) has ownership in the form of a patent licensed from MSKCC to Molecular MD, holds research grants with AstraZeneca, Roche, Symphogen and Kolltan, and consults with AstraZeneca, Merck, Novartis and Tocagen. LMC has received research and/or reagent support from Plexxikon, Inc., Pharmacyclics Inc., Acerta Pharma, LLC, Deciphera Pharmaceuticals, LLC, Genentech, Inc., Roche Glycart AG, Syndax Pharmaceuticals Inc. and Nanostring Technologies, Inc., is a paid consultant of Cell Signaling Technologies, is a member of the Scientific Advisory Boards for Syndax Pharmaceuticals, Inc., Carisma Therapeutics, Inc., Verseau Therapeutics, Inc.,and is a member of the PCYC-1137-CA steering committee for Pharmacyclics, Inc. sponsoring NCT02436668. LG provides consulting services to OmniSEQ, VL47 and Astrazeneca, is an industrial collaborator with Lytix Biopharma and Phosplatin, and is member of the Science Advisory Committee of OmniSEQ. LGR is a paid consultant with Lovance Biotherapeutics, BeiGene, and HUYA, a member of the scientific advisory boards at Macrophage Pharma (paid) and Aethlon Medical, and paid head of the scientific advisory board at SpeciCare. LHB is an advisory board member at SapVax, Simpatica and StemImmune, and participated in an advisory board call with Kite Pharma, Shire and Verastem. LS receives consulting fees from Allakos Inc.MC is an employee and shareholder of Abbvie. MTL receives salary compensation from UPMCE-ITTC and consulting fees from Torque, iRepertoire and Checkmate Pharmaceutical. MLA is an employee and stockholder of MedImmune. MLD receives royalties for patents held by the University of Washington and has contracted research with EMD Serono, Epithany, Pfizer, Janssen, Celgene, and Silverback Therapeutics. MP is an employee and shareholder of Abbvie. MQ is an employee and shareholder of Bristol-Myers Squibb. NPR is an employee of Weill Cornel Medicine. PAA serves as a consultant to Bristol-Myers Squibb, Roche, Merck, Novartis, Amgen, Array, Merck-Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, and MedImmune. He also receives research funding from Bristol-Myers Squibb, Roche and Array. RFS is a consultant and receives honoraria from Bristol-Myers Squibb, Exelixis, Puma Biotechnology, Eisai, and AstraZeneca, receives honoraria from Bristol-Myers Squibb and Exelixis, and receives research support from Bayer and Bristol-Myers Squibb. RL is an employee of Abbvie. RS has received consulting fees from Amgen, Abbvie, Bristol Meyer Squibb and Janssen. SC is an employee and stockholder of Nanostring. SS is a member of the scientific advisory board for Venn Therapeutics and an advisor to Replimune, TAKEDA, Ribon and Torque. SW is an employee and shareholder at Nanostring Technologies and has received travel reimbursement from Roche. VB is a consultant and serves on the Scientific Advisory Board for Illumina. WSH is a stockholder and board member of Lixte Biotechnology. All remaining authors declared no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.